COAG Stock Forecast: Hemab Therapeutics Holdings, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. hold a median 12-month price target of $64 — +62.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 2 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Hemab Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (29): Analysts have, on balance, been raising their forecasts.
Volatility (4): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
COAG stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on COAG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +62.9% from it.
Of the 14 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | LifeSci Capital | Initiates | Outperform | $65 |
| 15 Oct 2026 | JP Morgan | Initiates | Overweight | $70 |
| 12 Oct 2026 | Rodman & Renshaw | Initiates | Buy | $56 |
| 12 Aug 2026 | Wedbush | Maintains | Outperform | $55 → $64 |
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $52 → $60 |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $52 |
| 13 July 2026 | Jefferies | Maintains | Buy | $39 → $47 |
| 13 July 2026 | Wedbush | Maintains | Outperform | $42 → $55 |
| 26 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 26 May 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 26 May 2026 | Goldman Sachs | Initiates | Buy | — |
| 26 May 2026 | Jefferies | Initiates | Buy | — |
| 26 May 2026 | Wedbush | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for COAG.
This page is one stock. Monday covers all of them.
COAG appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
COAG vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
COAG analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 4.3×
- EV / EBITDA
- —
Cheaper than 22% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −32.8%
- Dividend yield
- —
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Hemab Therapeutics Holdings, Inc. has a market value of $1.8B and an enterprise value of $1.4B.
Hemab Therapeutics Holdings, Inc. employs 59 people.
Data provided by Twelve Data
COAG and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at COAG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Hemab Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about COAG
What is the COAG stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. have a median 12-month price target of $64, with estimates ranging from $54 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is COAG stock a buy right now?
Of the 7 analysts covering Hemab Therapeutics Holdings, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hemab Therapeutics Holdings, Inc. 2 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank COAG?
As at 21 Nov 2026, Hemab Therapeutics Holdings, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (29 of 100).
Will COAG stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +62.9% from the last close, and Ticker Nerd's factor model ranks Hemab Therapeutics Holdings, Inc. 2 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the COAG stock forecast for 2030?
No analyst covering Hemab Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COAG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $54 to $70 over the next 12 months.
What does Hemab Therapeutics Holdings, Inc. do?
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Hemab Therapeutics Holdings, Inc. is advancing a pipeline of treatments designed to address serious inherited bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease.
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Hemab Therapeutics Holdings, Inc. is advancing a pipeline of treatments designed to address serious inherited bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its lead programs include sutacimig (HMB-001), a bispecific antibody, and HMB-002, a monovalent antibody, both being studied in clinical development for prophylactic use. The company’s work centers on bleeding and coagulation biology, with an emphasis on therapeutic approaches that target underlying disease mechanisms rather than symptom management. Hemab Therapeutics Holdings, Inc. operates as a research-driven biotechnology business serving the rare disease and hematology markets.
CEO Dr. Benny Sorensen M.D., Ph.D. · 59 employees · United States · https://www.hemab.com